Evaluation of a New Recovery-oriented Model of Psychiatric Inpatient Care
Launched by UNIVERSITY HOSPITAL, GENEVA · Feb 7, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to improve care for patients in psychiatric hospitals. The goal is to make treatment more personalized, involve family members more in the process, and allow patients to have a say in their own treatment plans. The researchers will first test this new approach in one ward and compare it to two other wards that will continue with the usual care. They want to see if this new model leads to less use of forceful measures, shorter hospital stays, better improvement in patients' mental health, and higher satisfaction among patients.
To participate in the study, patients need to be 18 years or older, currently staying in one of the three wards, and able to speak French. Those who cannot provide informed consent or do not speak French well enough will not be eligible. If you join the study, you will be assessed when you leave the hospital to see how the new care model has affected your experience and recovery. The trial will last for 18 months, with the first 9 months testing the new approach in the pilot ward and then expanding it to the other two wards.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients hospitalized in one of the three participating wards
- Exclusion Criteria:
- • Incapacity to give informed consent
- • Insufficient knowledge of French
About University Hospital, Geneva
The University Hospital of Geneva is a leading academic medical center committed to advancing healthcare through innovative research and clinical excellence. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge medical research with high-quality patient care, fostering a collaborative environment that encourages the translation of scientific discoveries into practical treatments. As a prominent sponsor of clinical trials, the University Hospital of Geneva is dedicated to exploring new therapies and improving patient outcomes, while adhering to the highest ethical standards and regulatory compliance. Its robust infrastructure and expert clinical teams ensure the efficient execution of trials across various medical specialties, contributing significantly to the advancement of global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thônex, , Switzerland
Patients applied
Trial Officials
Alexandre Wullschleger, MD
Principal Investigator
University Hospital, Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported